Rectal Bleeding in a 3-Year-Old: Tranexamic Acid (TXA) and Vitamin K

First, establish the etiology - it drives the decision

• Anal fissure (most common in this age group - painful defecation, blood coating stool)
• Meckel diverticulum (painless, massive, brick-red bleeding)
• Intussusception (colicky pain, "currant jelly" stool)
• Infectious/allergic colitis (mucoid, bloody diarrhea)
• Polyps (painless, intermittent bright red blood)
• Henoch-Schonlein Purpura (purpuric rash + GI bleeding)
• Bleeding diathesis / coagulopathy

Tranexamic Acid (TXA)

• There are no pediatric-specific RCTs for TXA in GI bleeding. The textbook (Miller's Anesthesia) explicitly states: "large studies in pediatric patients are presently lacking."
• Adult evidence is mixed and concerning:
  • The HALT-IT RCT (Roberts et al., 2021) - a large adult trial - showed TXA had no effect on mortality in GI bleeding and actually found increased risk of venous thromboembolism (VTE) and seizures with high-dose infusion.
  • A 2025 meta-analysis (Calderon Martinez et al.) found TXA reduced rebleeding and mortality in upper GI bleeding, but was associated with increased mortality in lower GI bleeding (RR 1.67).
  • A large 2024 retrospective cohort found TXA in upper GI bleed was associated with increased MI, stroke, PE, and DVT.

"There is currently no evidence regarding the use of tranexamic acid in children and young people with upper GI bleeding... We recommend TXA should NOT be used routinely... However it may be warranted in extreme cases if other treatments fail and following MDT discussion."

• 15 mg/kg IV over 10 minutes (max 1 g), then 2 mg/kg/hr for 8 hours (max 1 g over 8 hours) (ACH PCCG Severe GI Bleeding Guideline, January 2026)

Vitamin K

"All patients should be administered intravenous proton pump inhibitor and vitamin K when upper GI bleed [is present]."

• Vitamin K deficiency can cause or worsen GI bleeding (it is even listed in the differential - "Hemorrhagic disease/Vitamin K deficiency" in Tintinalli's Table 134-1).
• It is safe, well-tolerated, and corrects any occult coagulopathy contributing to bleeding.
• Even if coagulation studies are normal, a single therapeutic dose has minimal risk and potential benefit.

Summary Table

Priority Actions

1. Assess hemodynamic stability first - resuscitate if needed (10 mL/kg 0.9% NaCl bolus).
2. Check CBC, coagulation studies (PT/PTT), type and screen.
3. Give IV PPI + Vitamin K as supportive care.
4. Identify the etiology (clinical exam, Meckel scan if massive painless bleed, surgical consult).
5. Reserve TXA for refractory, life-threatening hemorrhage unresponsive to other measures, only after pediatric surgical/GI/intensivist discussion.

• Rosen's Emergency Medicine, Pediatric GI Bleeding, Chapter 166
• Tintinalli's Emergency Medicine, Table 134-1
• NHS Scotland Paediatric UGI Bleed Guideline (2023)
• ACH PCCG Severe GI Bleeding Guideline (January 2026)
• HALT-IT RCT (Roberts et al., 2021 - PMID referenced in NHS guideline)

1. ACH PCCG Severe GI Bleeding Guideline (January 2026) - most recent institutional protocol
2. Sydney Children's Hospital GI Bleeding Guideline v4.1 (November 2025)
3. NHS Scotland Paediatric UGIB Guideline (2023)
4. PMC Octreotide Pediatric Review (2025) - PMID 41045337
5. Xu et al. Systematic Review, World J Pediatr (2025) - PMID 41045337

Tranexamic Acid in Pediatric GI Bleeding: Latest Research Evidence

The Core Problem

1. Landmark Adult RCT: HALT-IT (2021)

2. Most Comprehensive Meta-Analysis (2025)

3. IV TXA Meta-Analysis of RCTs Only (2025)

4. Dionne et al. Meta-Analysis (2022) - Dose Matters

5. TXA in Variceal/Cirrhotic UGIB (2024 RCT)

6. TXA in Lower GI Bleeding - Direct RCT (2024)

7. Pediatric Surgical TXA - the Only Pediatric Evidence Base

• TXA reduces postoperative blood loss and transfusions in pediatric surgery
• No significant adverse events compared to placebo in children
• Recommended dosing: loading dose 10-15 mg/kg, then 1-5 mg/kg/hr infusion
• Effect size similar regardless of cumulative dose used
• No pediatric GI bleeding RCTs existed at time of review

The pediatric safety data from surgery is reassuring, but cannot be directly extrapolated to GI bleeding - the mechanism and risk profile differ.

Summary: Evidence Map for Pediatric GI Bleed Decision

TXA in UGIB (upper GI / variceal)
────────────────────────────────────
Adult evidence:    Reduces rebleeding ✓
                   Reduces mortality in some subgroups ✓ (cirrhotic UGIB)
                   High-dose long infusion: VTE + seizure risk ✗
                   Low-dose: relatively safe profile ✓
Pediatric GI data: NONE
Pediatric surgery: Safe and effective ✓
Protocol stance:   ACH PCCG 2026 → USE (CRASH dosing)
                   NHS Scotland 2023 → Avoid routinely; MDT only

TXA in LGIB (lower GI / rectal bleeding)
────────────────────────────────────────
Adult evidence:    No benefit on transfusion (RCT 2024) ✗
                   67% increased mortality signal (meta-analysis 2025) ✗
                   ACG guideline: RECOMMENDS AGAINST use ✗
Pediatric GI data: NONE
Protocol stance:   ALL major protocols → DO NOT USE

What Guidelines Currently Say (2025-2026)

Bottom Line for Clinicians

1. No pediatric GI bleeding RCT exists for TXA - this gap is the fundamental problem.
2. For pediatric UGIB: cautious use of low-dose TXA (CRASH protocol: 15 mg/kg over 10 min, max 1 g; then 2 mg/kg/hr x 8h, max 1 g) is supported by the 2026 ACH guidelines and indirect evidence. Avoid high-dose prolonged infusion.
3. For pediatric LGIB / rectal bleeding: avoid TXA - adult evidence shows no benefit and potential mortality harm; ACG 2025 guidelines recommend against it.
4. Pediatric surgery data (50 RCTs) confirms TXA is safe in children at dosing of 10-15 mg/kg loading + 1-5 mg/kg/hr, providing some reassurance about the drug class in this age group.
5. Urgent need: a dedicated pediatric GI bleeding TXA trial is required before confident recommendations can be made.